320 related articles for article (PubMed ID: 15548877)
21. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies.
McDougall SR; Anderson AR; Chaplain MA; Sherratt JA
Bull Math Biol; 2002 Jul; 64(4):673-702. PubMed ID: 12216417
[TBL] [Abstract][Full Text] [Related]
22. Nonlinear simulation of tumor growth.
Cristini V; Lowengrub J; Nie Q
J Math Biol; 2003 Mar; 46(3):191-224. PubMed ID: 12728333
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
24. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
Kukowska-Latallo JF; Candido KA; Cao Z; Nigavekar SS; Majoros IJ; Thomas TP; Balogh LP; Khan MK; Baker JR
Cancer Res; 2005 Jun; 65(12):5317-24. PubMed ID: 15958579
[TBL] [Abstract][Full Text] [Related]
26. Predicting DNA-mediated drug delivery in interior carcinoma using electromagnetically excited nanoparticles.
Ghosh S; Das T; Chakraborty S; Das SK
Comput Biol Med; 2011 Sep; 41(9):771-9. PubMed ID: 21752360
[TBL] [Abstract][Full Text] [Related]
27. Active targeting schemes for nanoparticle systems in cancer therapeutics.
Byrne JD; Betancourt T; Brannon-Peppas L
Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.
ten Hagen TL; Seynhaeve AL; Eggermont AM
Immunol Rev; 2008 Apr; 222():299-315. PubMed ID: 18364010
[TBL] [Abstract][Full Text] [Related]
29. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
30. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
32. Transport of nanoparticles in magnetic targeting: Comparison of magnetic, diffusive and convective forces and fluxes in the microvasculature, through vascular pores and across the interstitium.
Kolitsi LI; Yiantsios SG
Microvasc Res; 2020 Jul; 130():104007. PubMed ID: 32305349
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
34. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
35. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
36. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
Botella P; Abasolo I; Fernández Y; Muniesa C; Miranda S; Quesada M; Ruiz J; Schwartz S; Corma A
J Control Release; 2011 Dec; 156(2):246-57. PubMed ID: 21756949
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C; Feron O
Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
Sun TM; Du JZ; Yao YD; Mao CQ; Dou S; Huang SY; Zhang PZ; Leong KW; Song EW; Wang J
ACS Nano; 2011 Feb; 5(2):1483-94. PubMed ID: 21204585
[TBL] [Abstract][Full Text] [Related]
39. Optimization of vascular-targeting drugs in a computational model of tumor growth.
Gevertz J
Phys Rev E Stat Nonlin Soft Matter Phys; 2012 Apr; 85(4 Pt 1):041914. PubMed ID: 22680505
[TBL] [Abstract][Full Text] [Related]
40. Resistance to antitumor chemotherapy due to bounded-noise-induced transitions.
d'Onofrio A; Gandolfi A
Phys Rev E Stat Nonlin Soft Matter Phys; 2010 Dec; 82(6 Pt 1):061901. PubMed ID: 21230684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
